Lumentum Holdings Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Lumentum Holdings Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jun 29, 2019 | $404.60M | Aug 27, 2019 |
| FY2019 | Mar 30, 2019 | $432.90M | Aug 27, 2019 |
| FY2019 | Dec 29, 2018 | $373.70M | Aug 27, 2019 |
| FY2019 | Sep 29, 2018 | $354.10M | Aug 27, 2019 |
| FY2019 | Jun 30, 2018 | $301.10M | Aug 27, 2019 |
| FY2019 | Mar 31, 2018 | $298.80M | Aug 27, 2019 |
| FY2019 | Dec 30, 2017 | $404.60M | Aug 27, 2019 |
| FY2019 | Sep 30, 2017 | $243.20M | Aug 27, 2019 |
| FY2018 | Jul 1, 2017 | $222.70M | Aug 28, 2018 |
| FY2018 | Apr 1, 2017 | $255.80M | Aug 28, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $1.65B | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | $1.36B | Aug 19, 2025 |
| FY2025 | Jul 1, 2023 | $1.77B | Aug 19, 2025 |
| FY2024 | Jul 2, 2022 | $1.71B | Aug 21, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jul 1, 2017 | $222.70M | Mar 29, 2018 |
| FY2017 | Apr 1, 2017 | $255.80M | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $265.00M | Mar 29, 2018 |
| FY2017 | Oct 1, 2016 | $258.10M | Mar 29, 2018 |
| FY2017 | Jul 2, 2016 | $241.70M | Mar 29, 2018 |
| FY2017 | Apr 2, 2016 | $230.40M | Mar 29, 2018 |
| FY2017 | Dec 26, 2015 | $218.30M | Mar 29, 2018 |
| FY2017 | Sep 26, 2015 | $212.60M | Mar 29, 2018 |
| FY2016 | Jun 27, 2015 | $208.90M | Sep 2, 2016 |
| FY2016 | Mar 28, 2015 | $198.70M | Sep 2, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $459.90M | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | $251.50M | Aug 19, 2025 |
| FY2025 | Jul 1, 2023 | $569.00M | Aug 19, 2025 |
| FY2024 | Jul 2, 2022 | $788.60M | Aug 21, 2024 |
| FY2021 | Jul 3, 2021 | $162.80M | Aug 31, 2021 |
| FY2021 | Apr 3, 2021 | $185.00M | Aug 31, 2021 |
| FY2021 | Dec 26, 2020 | $229.60M | Aug 31, 2021 |
| FY2021 | Sep 26, 2020 | $205.70M | Aug 31, 2021 |
| FY2021 | Jun 27, 2020 | $135.70M | Aug 31, 2021 |
| FY2021 | Mar 28, 2020 | $157.70M | Aug 31, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $25.90M | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | ($546.50M) | Aug 19, 2025 |
| FY2025 | Jul 1, 2023 | ($131.60M) | Aug 19, 2025 |
| FY2024 | Jul 2, 2022 | $198.90M | Aug 21, 2024 |
| FY2021 | Jul 3, 2021 | $21.50M | Aug 31, 2021 |
| FY2021 | Apr 3, 2021 | $225.50M | Aug 31, 2021 |
| FY2021 | Dec 26, 2020 | $83.20M | Aug 31, 2021 |
| FY2021 | Sep 26, 2020 | $67.10M | Aug 31, 2021 |
| FY2021 | Jun 27, 2020 | ($4.60M) | Aug 31, 2021 |
| FY2021 | Mar 28, 2020 | $43.40M | Aug 31, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | ($180.10M) | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | ($434.00M) | Aug 19, 2025 |
| FY2025 | Jul 1, 2023 | ($115.70M) | Aug 19, 2025 |
| FY2024 | Jul 2, 2022 | $303.30M | Aug 21, 2024 |
| FY2021 | Jul 3, 2021 | $45.80M | Aug 31, 2021 |
| FY2021 | Apr 3, 2021 | $266.90M | Aug 31, 2021 |
| FY2021 | Dec 26, 2020 | $115.30M | Aug 31, 2021 |
| FY2021 | Sep 26, 2020 | $99.00M | Aug 31, 2021 |
| FY2021 | Jun 27, 2020 | $27.00M | Aug 31, 2021 |
| FY2021 | Mar 28, 2020 | $42.50M | Aug 31, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $303.90M | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | $302.20M | Aug 19, 2025 |
| FY2025 | Jul 1, 2023 | $307.80M | Aug 19, 2025 |
| FY2024 | Jul 2, 2022 | $220.70M | Aug 21, 2024 |
| FY2021 | Jul 3, 2021 | $54.10M | Aug 31, 2021 |
| FY2021 | Apr 3, 2021 | $57.20M | Aug 31, 2021 |
| FY2021 | Dec 26, 2020 | $52.80M | Aug 31, 2021 |
| FY2021 | Sep 26, 2020 | $50.40M | Aug 31, 2021 |
| FY2021 | Jun 27, 2020 | $49.00M | Aug 31, 2021 |
| FY2021 | Mar 28, 2020 | $48.70M | Aug 31, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $348.20M | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | $310.70M | Aug 19, 2025 |
| FY2025 | Jul 1, 2023 | $348.80M | Aug 19, 2025 |
| FY2024 | Jul 2, 2022 | $265.70M | Aug 21, 2024 |
| FY2021 | Jul 3, 2021 | $58.30M | Aug 31, 2021 |
| FY2021 | Apr 3, 2021 | $65.50M | Aug 31, 2021 |
| FY2021 | Dec 26, 2020 | $61.30M | Aug 31, 2021 |
| FY2021 | Sep 26, 2020 | $56.30M | Aug 31, 2021 |
| FY2021 | Jun 27, 2020 | $54.80M | Aug 31, 2021 |
| FY2021 | Mar 28, 2020 | $61.30M | Aug 31, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $126.30M | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | $24.70M | Aug 19, 2025 |
| FY2025 | Jul 1, 2023 | $179.80M | Aug 19, 2025 |
| FY2024 | Jul 2, 2022 | $459.30M | Aug 21, 2024 |
| FY2023 | Jul 3, 2021 | $738.70M | Aug 23, 2023 |
| FY2022 | Jun 27, 2020 | $524.30M | Aug 24, 2022 |
| FY2021 | Jun 29, 2019 | $330.10M | Aug 31, 2021 |
| FY2020 | Jun 30, 2018 | $247.50M | Aug 25, 2020 |
| FY2019 | Jul 1, 2017 | $85.00M | Aug 27, 2019 |
| FY2018 | Jul 2, 2016 | $86.60M | Aug 28, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $231.00M | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | $133.00M | Aug 19, 2025 |
| FY2025 | Jul 1, 2023 | $128.50M | Aug 19, 2025 |
| FY2024 | Jul 2, 2022 | $91.20M | Aug 21, 2024 |
| FY2023 | Jul 3, 2021 | $84.80M | Aug 23, 2023 |
| FY2022 | Jun 27, 2020 | $86.00M | Aug 24, 2022 |
| FY2021 | Jun 29, 2019 | $166.00M | Aug 31, 2021 |
| FY2020 | Jun 30, 2018 | $93.20M | Aug 25, 2020 |
| FY2019 | Jul 1, 2017 | $138.10M | Aug 27, 2019 |
| FY2018 | Jul 2, 2016 | $82.00M | Aug 28, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $4.22B | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | $3.93B | Aug 19, 2025 |
| FY2024 | Jul 1, 2023 | $4.63B | Aug 21, 2024 |
| FY2023 | Jul 2, 2022 | $4.16B | Aug 23, 2023 |
| FY2022 | Jul 3, 2021 | $3.55B | Aug 24, 2022 |
| FY2021 | Jun 27, 2020 | $3.29B | Aug 31, 2021 |
| FY2020 | Jun 29, 2019 | $2.72B | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $1.58B | Aug 27, 2019 |
| FY2018 | Jul 1, 2017 | $1.23B | Aug 28, 2018 |
| FY2017 | Jul 2, 2016 | $726.30M | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $3.08B | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | $2.97B | Aug 19, 2025 |
| FY2024 | Jul 1, 2023 | $3.28B | Aug 21, 2024 |
| FY2023 | Jul 2, 2022 | $2.29B | Aug 23, 2023 |
| FY2022 | Jul 3, 2021 | $1.58B | Aug 24, 2022 |
| FY2021 | Jun 27, 2020 | $1.54B | Aug 31, 2021 |
| FY2020 | Jun 29, 2019 | $1.22B | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $619.60M | Aug 27, 2019 |
| FY2018 | Jul 1, 2017 | $578.30M | Aug 28, 2018 |
| FY2017 | Jul 2, 2016 | $193.10M | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $1.13B | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | $957.30M | Aug 19, 2025 |
| FY2025 | Jul 1, 2023 | $1.36B | Aug 19, 2025 |
| FY2025 | Jul 2, 2022 | $1.88B | Aug 19, 2025 |
| FY2024 | Jul 3, 2021 | $1.97B | Aug 21, 2024 |
| FY2023 | Jun 27, 2020 | $1.75B | Aug 23, 2023 |
| FY2022 | Jun 29, 2019 | $1.50B | Aug 24, 2022 |
| FY2021 | Jun 30, 2018 | $926.10M | Aug 31, 2021 |
| FY2020 | Jul 1, 2017 | $618.80M | Aug 25, 2020 |
| FY2019 | Jul 2, 2016 | $497.40M | Aug 27, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $1.06B | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | $1.06B | Aug 19, 2025 |
| FY2025 | Jul 1, 2023 | $695.10M | Aug 19, 2025 |
| FY2024 | Jul 2, 2022 | $368.90M | Aug 21, 2024 |
| FY2022 | Jul 3, 2021 | $368.90M | Aug 24, 2022 |
| FY2021 | Jun 27, 2020 | $368.90M | Aug 31, 2021 |
| FY2020 | Jun 29, 2019 | $368.90M | Aug 25, 2020 |
| FY2020 | Jun 30, 2018 | $11.30M | Aug 25, 2020 |
| FY2019 | Jul 1, 2017 | $11.40M | Aug 27, 2019 |
| FY2017 | Feb 28, 2017 | $5.60M | Mar 29, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | ($861.20M) | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | ($887.10M) | Aug 19, 2025 |
| FY2024 | Jul 1, 2023 | ($340.60M) | Aug 21, 2024 |
| FY2023 | Jul 3, 2022 | ($43.50M) | Aug 23, 2023 |
| FY2023 | Jul 2, 2022 | ($129.10M) | Aug 23, 2023 |
| FY2022 | Jul 3, 2021 | $220.90M | Aug 24, 2022 |
| FY2021 | Jun 27, 2020 | $64.60M | Aug 31, 2021 |
| FY2020 | Jun 29, 2019 | $129.10M | Aug 25, 2020 |
| FY2019 | Jul 1, 2018 | $165.80M | Aug 27, 2019 |
| FY2019 | Jun 30, 2018 | $166.40M | Aug 27, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | $520.70M | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | $436.70M | Aug 19, 2025 |
| FY2024 | Jul 1, 2023 | $859.00M | Aug 21, 2024 |
| FY2023 | Jul 2, 2022 | $1.29B | Aug 23, 2023 |
| FY2022 | Jul 3, 2021 | $774.30M | Aug 24, 2022 |
| FY2021 | Jun 27, 2020 | $298.00M | Aug 31, 2021 |
| FY2020 | Jun 29, 2019 | $432.60M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $397.30M | Aug 27, 2019 |
| FY2018 | Jul 1, 2017 | $272.90M | Aug 28, 2018 |
| FY2018 | Jul 2, 2016 | $157.10M | Aug 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jul 2, 2022 | $2.41B | Aug 24, 2022 |
| FY2021 | Jul 3, 2021 | $1.53B | Aug 31, 2021 |
| FY2020 | Jun 27, 2020 | $1.54B | Aug 25, 2020 |
| FY2018 | Jun 30, 2018 | $456.70M | Aug 28, 2018 |
| FY2017 | Jul 1, 2017 | $457.30M | Mar 29, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | 0 | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | (8) | Aug 19, 2025 |
| FY2025 | Jul 1, 2023 | (1) | Aug 19, 2025 |
| FY2024 | Jul 2, 2022 | 2 | Aug 21, 2024 |
| FY2021 | Jul 3, 2021 | 0 | Aug 31, 2021 |
| FY2021 | Apr 3, 2021 | 2 | Aug 31, 2021 |
| FY2021 | Dec 26, 2020 | 1 | Aug 31, 2021 |
| FY2021 | Sep 26, 2020 | 0 | Aug 31, 2021 |
| FY2021 | Jun 27, 2020 | 0 | Aug 31, 2021 |
| FY2021 | Mar 28, 2020 | 0 | Aug 31, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | 0 | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | (8) | Aug 19, 2025 |
| FY2025 | Jul 1, 2023 | (1) | Aug 19, 2025 |
| FY2024 | Jul 2, 2022 | 2 | Aug 21, 2024 |
| FY2021 | Jul 3, 2021 | 0 | Aug 31, 2021 |
| FY2021 | Apr 3, 2021 | 2 | Aug 31, 2021 |
| FY2021 | Dec 26, 2020 | 1 | Aug 31, 2021 |
| FY2021 | Sep 26, 2020 | 0 | Aug 31, 2021 |
| FY2021 | Jun 27, 2020 | 0 | Aug 31, 2021 |
| FY2021 | Mar 28, 2020 | 0 | Aug 31, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 28, 2025 | 69.80M | Aug 19, 2025 |
| FY2025 | Jun 29, 2024 | 67.90M | Aug 19, 2025 |
| FY2024 | Jul 1, 2023 | 66.40M | Aug 21, 2024 |
| FY2023 | Jul 2, 2022 | 68.00M | Aug 23, 2023 |
| FY2022 | Jul 3, 2021 | 73.00M | Aug 24, 2022 |
| FY2021 | Jun 27, 2020 | 75.10M | Aug 31, 2021 |
| FY2020 | Jun 29, 2019 | 76.65M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | 62.79M | Aug 27, 2019 |
| FY2018 | Jul 1, 2017 | 61.48M | Aug 28, 2018 |
| FY2017 | Jul 2, 2016 | 59.58M | Mar 29, 2018 |